SSelectStock
Sign in

WOCKPHARMAWockhardt Limited

Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)

1,923.40
1.19%
59Decent

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)30,884.90
P/E144.76
P/B6.24
PEG0.26
ROE %4.00
ROCE %5.60
Debt / Equity0.42
EPS13.13
Revenue Growth %26.00
Profit Growth %553.20
Dividend Yield %0.00
Promoter Holding %51.02
FII Holding %14.79
DII Holding %
Beta0.93

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

Pullback to 21-EMALONG62%1,923.401,792.402,204.502.15
HOLDConviction 69%

The picture

  • Revenue growth: 26.0% YoY
  • Profit growth: 553.2% YoY
  • Debt/Equity: 0.42
  • RSI: 55
  • Price vs EMA21: above
  • Price vs SMA50: above
  • Pullback to 21-EMA signal (setup quality 62%)

Bull case

  • Revenue growth: 26.0% YoY
  • Profit growth: 553.2% YoY
  • Debt/Equity: 0.42
  • RSI: 55

Bear case

  • ROE: 4.0%
  • ROCE: 5.6%
  • MACD: bearish
  • Supertrend: bearish

Key risks

  • ROE: 4.0%
  • ROCE: 5.6%

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹1,923.40
Stop Loss
₹1,774.48
risk 7.7%
Target 1 (1.5R)
₹2,146.79
+11.6%
Target 2 (3R)
₹2,370.17
+23.2%
Support (20d)
₹1,792.40
Resistance (52w)
₹2,422.30
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹148.92/share
ATR (volatility)
₹73.91
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹73.91). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental
56
Technical
58
Momentum
66
Risk (safety)
54

Peers — Pharma

PGHL 0.78%
84
AJANTPHARM 1.45%
82
HESTERBIO 3.09%
81
LUPIN 1.44%
80
SUNPHARMA 1.23%
80
CORONA 0.78%
79

About

Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.